搜索
Veracyte Inc
VCYT添加自选
38.480USD
-0.420-1.08%
收盘 05/15, 16:00（美东）报价延迟15分钟
3.07B总市值
34.51市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.08%
5天
-4.80%
1月
+16.50%
6月
-2.21%
今年开始到现在
-8.60%
1年
+31.78%
TradingKey Veracyte Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Veracyte Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名6/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价47.82。中期看，股价处于平稳状态。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Veracyte Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Veracyte Inc亮点
亮点风险
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
业绩高增长
公司营业收入稳步增长，连续3年增长43.23%
估值合理
公司最新PE估值34.51，处于3年历史合理位
机构减仓
最新机构持股96.10M股，环比减少1.93%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值20.77K
分析师目标
根据
12
位分析师
买入
评级
47.818
目标均价
+25.01%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Veracyte Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Veracyte Inc简介
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
公司代码VCYT
公司Veracyte Inc
CEOStapley (Marc A)
网址https://www.veracyte.com/
相关品种
